通过对Jak和Stat蛋白的氨酸酸化向核发信号的多化物
K Shuai1, A Ziemiecki, A F Wilks
1Laboratory of Molecular Cell Biology, Rockefeller University, New York 10021-6399.
Nature
|December 9, 1993
概括
干扰素 (IFN) 通过氨酸酸化触发信号转换器和转录 (Stat) 蛋白激活的激活器. 这项研究表明,Janus酶1 (Jak1) 可能是对IFN和EGF的反应中酸化Stat91的关键酶.
科学领域:
- 细胞信号传递途径 细胞信号传递途径
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
背景情况:
- 干扰子 (IFN) 结合细胞表面受体,启动信号传导.
- 信号传感器和转录 (Stat) 蛋白的激活剂的氨酸酸化是一个关键的早期事件.
- 特定的氨酸激酶,氨酸激酶-2 (Tyk2) 和Janus激酶2 (Jak2),分别参与IFN-alpha和IFN-gamma信号传递.
研究的目的:
- 为了研究Stat和Jak蛋白质上的铁素酸化事件.
- 确定特定激酶在干扰素和表皮生长因子 (EGF) 信号通路中的作用.
主要方法:
- 用IFN-alpha,IFN-gamma和EGF进行细胞治疗.
- 在Stat和Jak蛋白中对氨酸酸化的分析.
- 通过不同的配体激酶激活的比较.
主要成果:
- 在Tyr701上,Stat91被IFN-alpha,IFN-gamma和EGF所酸化.
- 简氏酶1 (Jak1) 是由所有三种配体酸化的铁素.
- 每个连接体至少激活一个不同的激酶.
结论:
- 在Stat91中,Jak1是酸化Tyr701的潜在候选酶.
- 杰克1在IFN和EGF激活的信号通路中发挥作用.
- 干扰素和生长因子信号通路具有共同的组件和机制.
相关概念视频
Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Amplifying Signals via Second Messengers
Many receptor binding ligands are hydrophilic; they do not cross the cell membrane but bind to cell-surface receptors. Thus, their message must be relayed by second messengers present in the cell cytoplasm. There are several second messenger pathways, each with its own way of relaying information. For example, the G protein-coupled receptors can activate both phosphoinositol and cyclic AMP (cAMP) second messenger pathways. The phosphoinositol pathway is active when the receptor induces...
Amplifying Signals via Enzymatic Cascade
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
PI3K/mTOR/AKT Signaling Pathway
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a rapamycin-insensitive companion...
TGF - β Signaling Pathway
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...


